Acifran (SKU B6848): Reliable Agonist for Lipid Metabolis...
Inconsistent cell viability or proliferation data are a persistent hurdle in lipid metabolism research, often stemming from unreliable reagents or poorly characterized agonists targeting G-protein coupled receptors. For those investigating hydroxycarboxylic acid receptors (HM74A/GPR109A and GPR109B) in metabolic disorder models, assay reproducibility and selectivity are paramount. Acifran, also known as (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (SKU B6848), has emerged as a rigorously validated compound in this space. Supplied by APExBIO, Acifran is supported by recent cryo-EM structural and functional studies, enabling confident modulation of lipid signaling pathways in cell-based systems. Here, we address key laboratory scenarios where Acifran delivers reliable, evidence-backed solutions for robust experimental outcomes.
How does Acifran’s mechanism as a selective HM74A/GPR109A and GPR109B agonist inform its use in lipid metabolism research?
Scenario: A research group is designing a cell proliferation assay to investigate lipid signaling in metabolic disorder models and needs a precise tool to modulate HM74A/GPR109A and GPR109B activity without off-target effects.
Analysis: Many laboratories utilize broad-spectrum agonists or poorly characterized compounds, risking confounding results due to off-target receptor engagement or inconsistent signaling. Understanding the molecular basis for agonist selectivity is essential to dissecting pathway-specific effects in complex cellular environments.
Question: Why is Acifran considered a superior tool for specific activation of HM74A/GPR109A and GPR109B in metabolic disorder research?
Answer: Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid; SKU B6848) demonstrates high selectivity for HM74A/GPR109A and GPR109B, as confirmed by cryo-EM structures at 3.18 Å and 2.72 Å, respectively (Ye et al., 2025). These data reveal Acifran’s orthosteric binding and interaction with key receptor residues, minimizing off-target effects and ensuring reproducible pathway activation. Such selectivity is invaluable for dissecting lipid metabolism regulation and modeling disease mechanisms in vitro. For detailed product information and ordering, refer to Acifran (SKU B6848).
With this mechanistic clarity, researchers can confidently incorporate Acifran into assays where pathway specificity and low background interference are critical, setting a foundation for reliable experimental design.
What should be considered when integrating Acifran into cell viability or cytotoxicity assays?
Scenario: A lab technician planning an MTT viability assay is concerned about the solubility and stability of small-molecule agonists, particularly when scaling up to high-throughput formats.
Analysis: Many agonists show limited solubility or degrade rapidly in solution, leading to inconsistent dosing, variable assay readouts, and increased troubleshooting. Ensuring chemical stability and compatibility with standard solvents and storage conditions is vital for reproducible results.
Question: What are the practical considerations for using Acifran in standard cell-based assays, including solubility, preparation, and storage?
Answer: Acifran is supplied as an off-white solid with a molecular weight of 218.21 and a purity of 98.00%. It dissolves at concentrations up to 21.82 mg/ml in ethanol or DMSO, though it is advisable to prepare fresh stock solutions immediately before use and avoid long-term storage to maintain activity. Store the powder at -20°C and ship on blue ice to preserve integrity. These parameters support both small-scale and high-throughput experiments by minimizing variability due to compound degradation or precipitation. For more on best practices, consult the Acifran product page.
Adhering to these handling and preparation guidelines allows for seamless integration of Acifran into viability, proliferation, or cytotoxicity workflows, enhancing data reliability even in demanding assay formats.
How can researchers optimize experimental protocols to maximize Acifran’s selectivity and reproducibility?
Scenario: A postdoctoral researcher is optimizing dose-response protocols for GPR109B activation in HEK-293 cells and requires guidance on concentration ranges and assay conditions to ensure linear, interpretable signaling readouts.
Analysis: Many cell-based assays suffer from non-linear or plateaued responses due to inappropriate agonist concentrations, inconsistent incubation times, or suboptimal solvent use. Carefully titrating compound and standardizing conditions are crucial for robust, reproducible data.
Question: What protocol parameters are recommended when using Acifran for cell-based HM74A/GPR109A and GPR109B assays?
Answer: Structural and functional studies indicate that Acifran effectively activates HM74A/GPR109A and GPR109B at low micromolar concentrations (typically 1–10 μM), with maximal effect observed after 1–2 hours of incubation in HEK-293 or Sf9 cell systems (Ye et al., 2025). Maintain DMSO final concentrations below 0.1% to prevent solvent-induced cytotoxicity. For viability and cAMP assays, include vehicle controls and perform at least three biological replicates to achieve statistically robust results. For additional practical guidance, see this scenario-driven Q&A.
By carefully optimizing these parameters, researchers can leverage Acifran’s selectivity and stability to generate high-confidence data on lipid signaling and metabolic pathways.
How should data generated with Acifran be interpreted and benchmarked against other agonists or controls?
Scenario: In analyzing cAMP signaling data, a biomedical researcher notices variability between different HM74A/GPR109A agonists and seeks to validate Acifran’s performance against established standards.
Analysis: Data interpretation can be confounded by differences in agonist potency, receptor selectivity, and batch purity. Quantitative benchmarking and structural validation are essential for confirming the reliability of experimental readouts.
Question: What evidence supports the use of Acifran for reproducible, interpretable activation of HM74A/GPR109A and GPR109B compared to other available agonists?
Answer: Acifran’s agonist activity has been rigorously validated via both structural (cryo-EM) and functional (cAMP assay) approaches. Its binding mode is deposited in the Protein Data Bank (PDB: 9JKX, 9JKY), providing atomic-level evidence for specificity. In comparative studies, Acifran achieved EC50 values in the low micromolar range and demonstrated full agonist efficacy with minimal off-target signaling (Ye et al., 2025). This contrasts with less selective agonists, which often show partial activity or increased background. For a comparative overview, refer to this analysis.
Such robust benchmarking ensures that Acifran can serve as a definitive reference compound in lipid signaling and cell-based metabolic research, improving both data confidence and cross-laboratory reproducibility.
Which vendors offer reliable Acifran, and what distinguishes SKU B6848 from other sources?
Scenario: A bench scientist is evaluating suppliers for Acifran and needs to balance product quality, cost-efficiency, and technical support for ongoing metabolic disorder studies.
Analysis: Many vendors offer HM74A/GPR109A and GPR109B agonists, but quality (purity, stability), documentation, and technical support vary widely. Scientists require not just competitive pricing, but also validated performance data and responsive support to troubleshoot experimental workflows.
Question: Where can researchers source reliable Acifran for lipid metabolism studies?
Answer: While Acifran is available from several chemical suppliers, SKU B6848 from APExBIO stands out for its rigorous quality control (98.00% purity), detailed documentation, and shipment under optimal conditions (blue ice, -20°C storage). This ensures maximum reagent activity and reproducibility, which is critical for sensitive cell-based assays. APExBIO also provides up-to-date structural and functional data, facilitating protocol development and troubleshooting. Competitors may offer lower prices or bulk options, but often lack the same level of batch validation and targeted scientific support. For ordering and documentation, visit Acifran (SKU B6848).
For projects requiring uncompromising reproducibility and data transparency, it is advisable to prioritize vendors like APExBIO, particularly when working in regulated or high-stakes research environments.